A Leclercq1, B Gauthier2, V Rosner3, L Weiss4, F Moreau5, A A Constantinescu6, R Kessler3, L Kessler7. 1. Service de pneumologie et CRCM adulte, Hôpitaux Universitaires de Strasbourg, 1 place de l'hôpital, 67091 Strasbourg, France. Electronic address: aleclercq1@gmail.com. 2. CRCM, Hôpitaux Universitaires de Reims, 47, rue Cognacq-Jay, 51092 Reims, France. 3. Service de pneumologie et CRCM adulte, Hôpitaux Universitaires de Strasbourg, 1 place de l'hôpital, 67091 Strasbourg, France. 4. CRCM pédiatrique, Hôpitaux Universitaires de Strasbourg, 1 Avenue Molière, 67098 Strasbourg, France. 5. Service d'endocrinologie et de diabétologie, Hôpitaux Universitaires de Strasbourg, 1 place de l'hôpital, 67091 Strasbourg, France. 6. EA 7293, Vascular and Tissue Stress in Transplantation, Federation of Translational Medicine of Strasbourg, University of Strasbourg, France; Department of Parasitology and Parasitic Diseases and Animal Biology, Faculty of Veterinary Medicine, University of Agronomical Sciences and Veterinary Medicine, Bucharest, Romania. 7. Service d'endocrinologie et de diabétologie, Hôpitaux Universitaires de Strasbourg, 1 place de l'hôpital, 67091 Strasbourg, France; EA 7293, Vascular and Tissue Stress in Transplantation, Federation of Translational Medicine of Strasbourg, University of Strasbourg, France.
Abstract
BACKGROUND: Cystic fibrosis-related diabetes (CFRD) is correlated with a decline in lung function. Under certain circumstances, oral glucose tolerance test (OGTT) screening, used to diagnose CFRD, fails to reveal early glucose tolerance abnormalities. In this situation, continuous glucose monitoring (CGM) could be a useful tool for evaluating early abnormalities of glucose tolerance in CF patients. We aimed to study the CGM glucose profile in CF patients with normal OGTT screening results and to evaluate lung function and nutritional status according to the CGM glucose profile. METHODS: We assessed glycemic control, the CGM glucose profile, nutritional status, lung function antibiotic courses and colonization (P. aeruginosa and S. aureus) in CF patients, aged 10 years and over, with normal screening OGTT results (blood glucose at T120 min < 7.8 mmol/l). Two groups were identified according to the max CGM glucose value: Group 1<11 mmol/l and Group 2 ≥ 11 mmol/l. RESULTS: Among the 38 patients with normal OGTT, 12 (31.6%) were in Group 2. Compared to Group 1, Group 2 patients exhibited a significant impairment in lung function: FEV1, 68.2 ± 25.6% vs. 87.3 ± 17%, p = 0.01 and FVC, 86.1% ± 19.4% vs. 99.3% ± 13.4%, p=0.021, as well as a higher rate of colonization by P. aeruginosa: 83.3% vs. 44%, p=0.024. Nevertheless, there were no differences in nutritional status (BMI standard deviation score: p = 0.079; prealbumin: p = 0.364). CONCLUSIONS: CGM reveals early abnormalities of glucose tolerance that remain undiagnosed by OGTT screening and are associated with worse lung function and a higher prevalence of P. aeruginosa colonization in patients with CF. CLINICAL TRIAL REGISTRATION NUMBER: NCT00476281.
BACKGROUND: Cystic fibrosis-related diabetes (CFRD) is correlated with a decline in lung function. Under certain circumstances, oral glucose tolerance test (OGTT) screening, used to diagnose CFRD, fails to reveal early glucose tolerance abnormalities. In this situation, continuous glucose monitoring (CGM) could be a useful tool for evaluating early abnormalities of glucose tolerance in CFpatients. We aimed to study the CGM glucose profile in CFpatients with normal OGTT screening results and to evaluate lung function and nutritional status according to the CGM glucose profile. METHODS: We assessed glycemic control, the CGM glucose profile, nutritional status, lung function antibiotic courses and colonization (P. aeruginosa and S. aureus) in CFpatients, aged 10 years and over, with normal screening OGTT results (blood glucose at T120 min < 7.8 mmol/l). Two groups were identified according to the max CGM glucose value: Group 1<11 mmol/l and Group 2 ≥ 11 mmol/l. RESULTS: Among the 38 patients with normal OGTT, 12 (31.6%) were in Group 2. Compared to Group 1, Group 2 patients exhibited a significant impairment in lung function: FEV1, 68.2 ± 25.6% vs. 87.3 ± 17%, p = 0.01 and FVC, 86.1% ± 19.4% vs. 99.3% ± 13.4%, p=0.021, as well as a higher rate of colonization by P. aeruginosa: 83.3% vs. 44%, p=0.024. Nevertheless, there were no differences in nutritional status (BMI standard deviation score: p = 0.079; prealbumin: p = 0.364). CONCLUSIONS: CGM reveals early abnormalities of glucose tolerance that remain undiagnosed by OGTT screening and are associated with worse lung function and a higher prevalence of P. aeruginosa colonization in patients with CF. CLINICAL TRIAL REGISTRATION NUMBER: NCT00476281.
Authors: Marissa J Kilberg; Clea Harris; Saba Sheikh; Darko Stefanovski; Marina Cuchel; Christina Kubrak; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958
Authors: Kevin J Scully; Jordan S Sherwood; Kimberly Martin; Melanie Ruazol; Peter Marchetti; Mary Larkin; Hui Zheng; Gregory S Sawicki; Ahmet Uluer; Isabel Neuringer; Lael M Yonker; Leonard Sicilian; Deborah J Wexler; Melissa S Putman Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 5.958
Authors: Kevin J Scully; Peter Marchetti; Gregory S Sawicki; Ahmet Uluer; Manuela Cernadas; Rebecca E Cagnina; John C Kennedy; Melissa S Putman Journal: J Cyst Fibros Date: 2021-09-14 Impact factor: 5.482
Authors: Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 6.134
Authors: Christine L Chan; Timothy Vigers; Laura Pyle; Philip S Zeitler; Scott D Sagel; Kristen J Nadeau Journal: J Cyst Fibros Date: 2018-03-23 Impact factor: 5.482
Authors: Charles D Bengtson; Michael D Kim; Abeer Anabtawi; Jianghua He; John S Dennis; Sara Miller; Makoto Yoshida; Nathalie Baumlin; Matthias Salathe Journal: Eur Respir J Date: 2021-01-14 Impact factor: 16.671